Przeglądanie według Temat "ulcerative colitis"

Aktualnie wyświetlane 1 - 4 z 4

Inflammatory bowel disease: clinical aspects
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2018) Pasternak, Grzegorz; Aebisher, David; Filip, Rafał; Bartusik-Aebisher, Dorota
Introduction. Inflammatory bowel disease is a complex disease which arises as a result of an interaction between environmental and genetic factors leading to immunological responses and inflammation in the intestine. Aim. To review medical approaches used in inflammatory bowel disorders. Materials and methods. An analysis of literature regarding inflammatory bowel diseases, Leśniowski-Crohn’s disease, ulcerative colitis and mataloproteinases. Results. Current evidence suggests that patients with inflammatory bowel disease may have an elevated risk of endothelial dysfunction and coronary artery disease. Over the past two decades, great advances have been made in our understanding of the interplay between the inflammatory bowel disease. Conclusions. Inflammatory bowel diseases are increasing in Europe. The diagnosis is usually confirmed by biopsies on colonoscopy.
Infliximab in therapy of inflammatory bowels diseases
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2019) Bar, Piotr; Galiniak, Sabina; Bartusik-Aebisher, Dorota; Filip, Rafał; Aebisher, David
Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases. Aim. This article reviewed the efficacy and safety of infliximab for the treatment in severe ulcerative colitis. This review included studies that evaluated the clinical use of infliximab. Material and methods. This meta-analysis was performed according to systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran). Results. Infliximab has been approved by the US Food and Drug Administration (FDA) as a medicine to treat Leśniowski and Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. However, further trials are required to compare other parameters of efficacy such as the clinical response with infliximab. Conclusion. In patients suffering from Crohn’s disease or ulcerative colitis under infliximab maintenance therapy, sustained good trough levels are associated with: better response and remission rates, more mucosal healing and less loss of response.
Macro and micronutrient deficiency in inflammatory bowel diseases
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2017) Jarmakiewicz, Sara; Piątek, Dominika; Filip, Rafał
Introduction. Inflammatory bowel disease (IBD) is group of global range inflammatory conditions. There has been a regular increase in the number of IBD cases. Patients exclude whole food groups from their diet fearing the emergence of disease symptoms or due to learning from unreliable sources. Doing so, they might deepen the already existing vitamin deficiencies which occur along with the shortage of many minerals. These deficiencies might intensify the disease process or cause a new one. The most common deficits pointed out by numerous researchers concern vitamin D, calcium, cobalamin, folic acid and iron. It is well worth introducing selenium, zinc and ascorbic acid into a diet because of their immunomodulating effect. Important aspect of the healing process is a personalized diet which is designed to compensate for, or prevent vitamin and mineral deficiencies. Aim. The purpose of the study was to review the literature about vitamin and mineral deficiency in Inflammatory Bowel Diseases. Materials and method. Analysis of literature.
Monitoring of infliximab treatment in inflammatory bowel diseases – basic knowledge and current data based on clinical trials in a population of Polish patients
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2022-12) Pękala, Anna
Introduction and aim. Infliximab is the oldest biological drug belonging to the group of tumor necrosis factor antagonists. Despite the availability of many new biological therapies, this drug still plays an important role in the treatment of inflammatory bowel diseases. However, a significant problem related to pharmacotherapy is the high inter-individual variability of the response. Material and methods. This study presents results of the research on the treatment with infliximab in the inflammatory bowel disease (IBD) patients including our own experience in Polish IBD patients. Analysis of the literature. Therapeutic failure while using infliximab can be attributed partly to inadequate serum concentrations of the drug and the development of anti-drug antibodies. Many studies have attempted to find a relationship between the specific level of infliximab and the achieved healing effect. These analyses show that the optimal level of the drug differs depending on the type of disease, its phenotype, and therapeutic goal and that the optimization of infliximab therapy remains an open topic. Two studies involving the population of Polish IBD patients examined the level of infliximab during and after induction, as well as the frequency of anti-drug antibodies. Two studies involving a population of Polish IBD patients examined the level of infliximab during and after induction, as well as the frequency of anti-drug antibodies. These studies demonstrated the need for monitoring infliximab treatment at weeks 6 and 14. Conclusion. Reactive monitoring is believed to enable the most rational treatment decisions; however, experts also recommend that proactive monitoring should measure infliximab concentrations at the end of induction and at least once during maintenance treatment.